GENE GTG Labs Expected net earnings per share growth this year
Slow adoption rates of genetic tests and the risk of share dilution due to secondary offerings are weighing on Genetic Technologies (GENE). Growth depends on the clinical validation of methodologies and laboratory throughput. The company generates capital through preventive diagnostics for cancer and diabetes. The annual earnings per share trend on GURU.Markets reflects a dynamic where the indicator remains around 0.00.
Financial and market metric breakdowns for gtglabs.com (GENE)
- current quotes and average value forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Debt to Equity Ratio Genetic Technologies|GENE - Long-Term Debt to Capital|Current Liabilities to Capital Genetic Technologies Limited|GENE - Company Total Debt|Debt to Book Capital Genetic Technologies Limited|GENE - Company Long-Term Debts|Short-Term Debt Volume Genetic Technologies|Quick Liquidity Indicator gtglabs.com
- business earnings and investment ratios data:
GENE - Net Income|Expected Net Income Genetic Technologies|GENE - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Genetic Technologies Limited|GENE - PEG Multiple|Company Value to EBITDA Genetic Technologies Limited|GENE - Operating profit EBITDA|Net earnings per share for the last 12 months Genetic Technologies|GENE - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months gtglabs.com|GENE - Earnings per share growth in current year|Projected earnings per share growth rate for next year Genetic Technologies
Summary company analysis:GTG Labs - GENE
For Genetic Technologies (GENE), which lacks stable revenue streams, profit dynamics depend critically on the commercial success of its oncology tests. By analyzing year-over-year EPS growth rates, an investor can observe the percentage change in net income per share relative to the previous year, adjusted for seasonality. A negative trajectory for this indicator signals a risk of capital freeze due to weak operational liquidity.
Direct competitors
A - Expected net earnings per share growth this year|Earnings per share growth in current year Quest|Illumina Platform (ILMN) - Expected net earnings per share growth this year|Earnings growth in current year EXAS|revvity.com (RVTY) - Net earnings per share change in current year|Earnings growth in current year BIO (Bio-Rad)|Anbio Biotechnology Ltd (NNNN) - Earnings per share growth rate in current year|SHC - Earnings per share growth in current year|QDEL (QuidelOrtho Inc.) - Earnings per share growth this year|OPK: Earnings growth in current year|Earnings per share growth rate in current year CareDx (CDNA)|Net earnings per share growth this year MRVI|FLGT (Fulgent Genetics Inc) - Net earnings per one share growth for the current year|Earnings growth in current year LAB|Expected net earnings per share growth this year Cytek Corp|Earnings growth in current year OSUR (OraSure Technologies)|XGN - Net earnings per share growth this year|MDXH: Net earnings per share growth this year|Earnings per share increase in current year LUCD (Lucid Diagnostics, Inc.)|PRE (prenetics.com) - Net earnings per share growth this year|IMDX: Net earnings per one share growth for the current year|TRIB (Trinity Biotech PLC) - Earnings growth in current year|Earnings per share growth rate in current year prophaselabs.com PRPH|Earnings growth in current year AIMD|Net earnings per share growth this year Co-Diagnostics Inc CODX|Earnings growth in current year HSCS (Heart Test Laboratories Inc.)|Earnings per share increase in current year BMRA|CDIO - Earnings per share growth in current year|ONCO (onconetix.gcs-web.com) - Earnings per share growth this year|Virax Biolabs (VRAX) - Earnings per share growth in current year|Earnings per share growth rate in current year Bluejay Diagnostics Inc (BJDX)|Earnings per share growth in current year Vermillion|Earnings per share growth in current year AXDX|Earnings per share growth in current year Centogene NV (CNTG)|ENZ - Earnings per share growth rate in current year|Earnings growth in current year FRES (Fresh2 Group)|Net earnings per share change in current year 23andMe Holding Co|Psychemedics Corp - Earnings growth in current year
